Suzhou, China, Palo Alto, California, USA May 20, 2021/PRNewswire/-Genxi Biotechnology Group (NASDAQ: GRCL；; Genxi Bio, a global clinical biopharmaceutical company dedicated to developing efficient and economical cell therapy for cancer treatment, announced today that it will publish the latest clinical research results of a multi-center, first-time human trial on GC012F in the treatment of relapsed/refractory multiple myeloma during the annual meeting of American Society of Clinical Oncology (ASCO) in 2021 and the conference of European Hematology Association (EHA) in 2021.

GC012F is a BCMA/CD19 dual-target autologous CAR-T cell therapy developed based on the patented technology platform of Genxi Bio-FasTCAR, which has the advantage of "production can be completed the next day". At present, the candidate product is being evaluated in a phase I clinical trial initiated by researchers.

• By January 12, 2021, 19 patients with multiple myeloma were enrolled in the three dose groups of this study, of which the highest dose level was 3×10.^fiveCells/kg body weight, all the above patients meet the criteria of recurrence/refractory after multiple rounds of treatment. Subsequent patients (after the release of data at the ASH annual meeting in 2020) received the highest dose level of treatment.
• The early objective remission rate (ORR) was as high as 94.7%(18/19), and all the responses showed that excellent partial remission (VGPR) and even complete remission (SCR) were obtained. The data of all dose groups showed a rapid, in-depth and lasting therapeutic effect.
• All patients (n=9) who received treatment in the highest dose group achieved negative minimal residual lesions-complete remission (MRD- sCR) in a strict sense.
• Of the 19 patients, 18 (94.7%) belonged to the high-risk patients defined in mSMART 3.0 guidelines, and the median number of previous treatment lines was 5.
• 94.7%(18/19) patients have been exposed to PI, IMiD and at least the third treatment scheme, including anti-CD38 targeted therapy.
• The safety of GC012F is consistent with the previous observation results, and the main symptom is low-grade cytokine release syndrome (CRS)(84% patients are grade 1/2; 11% (n=2) patients were grade 3), and there was no grade 4 or 5 CRS；. No immune effector cell-related neurotoxicity (ICANS) was observed in 19 patients. Adverse events (TEAEs) occurred during treatment were mainly manifested as decrease of blood cell count and increase of AST. All TEAEs were relieved after standard treatment.
• The study will continue to evaluate the effectiveness and safety of GC012F in the treatment of patients.

"I am glad to see the mutual evidence between the follow-up of the initial patients and the treatment effect of the subsequent patients, which not only confirms the research results announced at the annual meeting of ASH last year, but also further clarifies the excellent safety and effectiveness of GC012F dual-targeted autologous CAR-T cell therapy, including for high-risk patients."Chief Medical Officer of Genxi BiologydoctorIt said: "High-risk patients are usually extremely difficult to treat, but all patients in the highest dose group in this study have reached the MRD negative sCR state and maintained a deep response for six months or even longer after receiving GC012F infusion. The above exciting research data bring brand-new hope to high-risk patients (including those who do not respond to the standard treatment plan). Next, we plan to promote this research on a global scale, including promoting it as a more preferred treatment option. I look forward to sharing more developments with you in the near future. "

GC012FClinical research initiated by researchers (IIT) Co-principal researcher, Professor Du Fu of shanghai changzheng hospital."Multiple myeloma (MM) is a malignant blood tumor that is extremely difficult to treat. There are about 750,000 patients with multiple myeloma worldwide.^[1]There are about 160,000 new patients every year.^[2]And it is on the rise year by year. Among them, high-risk patients account for 20%-30%.^[3]The prognosis is usually poor, accompanied by higher risk of early recurrence, shorter progression-free survival and overall survival. This time, we are pleased to see that the BCMA/CD19 dual-target autologous CAR-T cell therapy GC012F of Genxi Bio has shown excellent effectiveness and safety for the long-term follow-up results of patients with relapsed/refractory multiple myeloma. And thanks to the advantages of FasTCAR platform, the waiting time of clinical treatment has been significantly shortened, and the hope of life has been ignited for more patients. "

GC012FClinical research initiated by researchers (IIT) Co-principal researcher, Professor Fu Weijun of shanghai changzheng hospital.Said: "I am very happy to see that after we announced the first human trial data of GC012F in the form of oral report at the ASH meeting last year, this research has made positive progress again, and the previous results have been further verified; This also allows us to see the good application prospects of Ganxi Bio-FasTCAR platform and Dual CAR technology. With the deepening of research, the clinical benefits of this innovative BCMA/CD19 dual-targeted autologous CAR-T cell therapy for patients with multiple myeloma, especially high-risk patients, are constantly emerging. It is expected that this research will continue to achieve more results and strive to meet the urgent treatment needs of patients with recurrent/refractory multiple myeloma as soon as possible. "

Details of the electronic poster are as follows:

2021American Society of Clinical Oncology (ASCO) annual meeting

abstract8014：Long-term follow-up results of the first multicenter human trial of BCMA/CD19 dual-target CAR-T cell therapy GC012F for patients with relapsed or refractory multiple myeloma based on FasTCAR platform.

Poster release date:June 4, 2021

2021European hematology association (EHA2021) conference

abstractEP962：Long-term follow-up results of the first multicenter human trial of BCMA/CD19 dual-target CAR-T cell therapy GC012F for patients with relapsed or refractory multiple myeloma based on FasTCAR platform.

Poster release date:June 11th, 2021

About multiple myeloma

Multiple myeloma (MM) is the third most common malignant hematological tumor in the United States. Its tumor cells originated from bone marrow plasma cells, an immune cell responsible for secreting anti-infective antibodies. About 160,000 patients worldwide are diagnosed with multiple myeloma every year; In 2020, the United States is expected to have more than 32,000 confirmed patients. In recent years, although many progress has been made in the treatment of multiple myeloma, the clinical treatment effect is still unsatisfactory. International Myeloma Working Group (IMWG) and the consensus guidelines of Mayo ST Rating for Myeloma and Risk-Adapted Therapy (MSMART) classify patients with specific cytogenetic abnormalities or other abnormalities as high-risk patients, and this group accounts for 20-30% of all patients with multiple myeloma. High-risk patients with high risk of early recurrence, progression-free survival and short overall survival are considered as the most difficult patients with multiple myeloma, and usually have poor prognosis.

aboutGC012F

GC012F is a candidate product for dual-target autologous CAR-T therapy based on FasTCAR platform. At present, the candidate product is evaluating its safety and effectiveness in the treatment of multiple myeloma in a multi-center and phase I clinical trial initiated by researchers, covering many research centers in China. GC012F brings rapid, in-depth and lasting therapeutic effects to patients with multiple myeloma by simultaneously targeting the malignant plasma cell site expressing BCMA and the early progenitor cell site expressing CD19.　

aboutFasTCAR

FasTCAR is a technology platform with intellectual property rights of Genxi Bio, aiming at developing high-quality autologous CAR-T cell therapy. Preclinical studies show that the phenotype of CAR-T cells produced by FasTCAR technology platform is younger, the degree of depletion is lower, and the amplification ability, persistence, bone marrow migration ability and tumor cell clearance activity are enhanced. With the advantage of "completing production the next day", FasTCAR platform technology can greatly improve cell production efficiency, thus significantly reducing production costs and enabling cell therapy to benefit more cancer patients.

About genxi creatures

Genxi Biotechnology Group (Genxi Bio for short) is a global clinical biopharmaceutical company dedicated to the discovery and development of breakthrough cell therapy. Using its pioneering FasTCAR and TruUCAR technology platforms, Genxi Bio is developing a number of rich clinical cancer treatment product pipelines, both autologous and allogeneic. These products are expected to overcome the persistent major industry challenges of traditional CAR-T therapy, including long production time, poor production quality, high treatment cost and lack of effective treatment for solid tumors. To learn more about Genxi Bio, please visit www.gracellbio.com/ Concern LinkedIn account @GracellBio.

Warning statement about forward-looking statements

The statement in the press release about future expectations, plans, prospects and other non-historical facts may contain a "forward-looking statement" as defined in the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the expected transaction and completion time of this offering. These statements may, but do not necessarily, contain the following words and corresponding negative forms or similar words: purpose, expectation, belief, estimation, prediction, plan, possibility, prospect, plan, potential, conjecture, formulation, seeking, possibility, should and will. Due to various important factors, the actual results may be significantly different from the forward-looking statements, and there is no guarantee that any forward-looking statements will be realized. These important factors include the factors mentioned in the Risk Factors section of Genxi Bio’s recent annual report in Form 20-F, and the discussion on potential risks, uncertainties and other important factors in Genxi Bio’s subsequent report to the US Securities Regulatory Commission after the session. Any forward-looking statements in this statement only reflect the current expectations, and Genxi Bio has no responsibility to publicly update or review any forward-looking statements, whether based on new information, future events or other reasons. Readers are requested not to rely on forward-looking statements after the publication date of this press release.

Media contact

marvin.tang@gracellbio.com

Investor contact

gracie.tong@gracellbio.com

　　Do you think the nightlife of young people may be

　　Disco dancing and KTV all night …

　　But in fact, the nightlife of contemporary young people is the favorite.

　　It’s the Health Bureau!

　　Recently in Hangzhou

　　Young people have "grasped" a new way to relax.

　　Go to the hospital massage department for massage.

　　It became something they were keen on punching in.

　　Walk into Zhejiang Traditional Chinese Medicine Hospital and Hangzhou Traditional Chinese Medicine Hospital together.

　　Look at the young people having a "party" in the massage clinic

　　What kind of experience is it!

　　Young people get together and massage ke

　　Talking too much is all about "pain, pain"

　　Around 18 o’clock, the massage clinic of Zhejiang Provincial Hospital of Traditional Chinese Medicine was almost full, many of them were young faces, and there were young people who had just left work outside. Dr. Ning Xitao said that during the peak period, doctors in departments have to receive more than 30 patients in one night clinic.

　　At this time, the massage doctors in Hangzhou Chinese Medicine Hospital are also busy. "The people who come at night are basically young people." Just after that, Dr. Qiu Zhengjun hung up the traction for the patient and called the next one to lie on the massage bed.

　　Why are there so many young people? Many reasons are "pain".

　　Ms. Wang, who is doing massage, is 25 years old. Her unit is near the hospital and she will come as soon as she gets off work. Recently, her shoulder and neck hurts badly. She comes to Dr. Qiu for massage and physical therapy every week: "I feel light after pushing for half an hour." She and her colleagues who are engaged in the financial industry are also "frequent visitors" to the Tuina Department. Sometimes they will make an appointment to "open a party" during their lunch break. "Just think of it as a group building."

　　The biggest affirmation is the trust of peers. Doctors from the maternity hospital next door to Zhejiang Provincial Hospital of Traditional Chinese Medicine also came to massage during dinner. After a massage for more than ten minutes, he exhaled a "cool"! "There are still several lumbar problems in our department." With that, he put on his shoes and went back to work at night.

　　After the "90s", Ms. Huang is a white-collar worker in the company and an "old patient" in the massage department. She comes from work almost every other day, and she also notices that more and more young people come here. "Everyone is here for treatment, not simply for relaxation."

　　Doctor’s reminder: treat it rationally

　　Massage is not recommended if you have nothing to do.

　　The young office workers who come to receive massage treatment at night have a lot of bad cervical vertebrae, and their age is basically between 20 and 40 years old, which shows an obvious trend of rejuvenation.

　　Dr. Qiu from the Municipal Hospital of Traditional Chinese Medicine explained: "Nowadays, young people are facing mobile phones and computers every day. With incorrect posture and no time to exercise, cervical and lumbar problems are getting younger and younger." He said that massage only helps to relieve the pain, and it is important to rely on young people to move themselves.

　　Dr. Ning from Provincial Hospital of Traditional Chinese Medicine said that many young people only know that hospitals can also do massage after watching the sharing on social platforms.

　　He said: "Three points depend on the rule, seven points depend on the support, mainly relying on their own to get rid of bad habits, and it is not recommended that young people come to massage when they have nothing to do."

　　It is worth mentioning that both Zhejiang Provincial Hospital of Traditional Chinese Medicine and Hangzhou Hospital of Traditional Chinese Medicine have massage clinics for children. At night, the clinic is full of children and parents. Different from adult massage which specializes in cervical vertebra and lumbar vertebra, children’s common medical problems can be solved in children’s massage clinic.

　　Text: Jia Kai Photography: Yang Zijian, Jia Kai

　　Original title: 2020 "The people of Shanghai went to Shanghai," launched 20 special tourism routes+20 cities good events, which one do you like?

　　The Shanghai Culture and Tourism Bureau sponsored the "Shanghai People’s Going to the Shanghai event since the month of 2020. 19. China Tourism Day starts the date of the city. Many fine lines and waste management activities. The annual activity abstract and review, and in order to better launch a new event in 2021, revealing a new one, especially the "fashion capital, Shanghai magic" 2020 "Shanghai people go to Shanghai to Shanghai "Online competition.

　　Among the candidates of more than 3.00 candidates, more than 200 events. Cultural tourism experts repeatedly decided after selecting 20 special tourism routes and good activities in 20 cities. These final players will be appointed by the regional cultural travel agency in December this year. , Representing this line to participate in the speech, it has a detailed series with activities in the region. In the final jury, the media selection of the "Shanghai People’s Favorite Micro Shanghai Tourism Road" and "Shanghai’s Most Popular Cities" in 2020. "This is a good look at Shanghai’s finals and urban events. Shanghai is good!

　　Special tourist route

　　Baoshan District: Post -industrial fashion new way

　　Many people carry the memories of the old industrial factories. The old yard sparks in industrial reorganization, becoming the most avant -garde of the landscape of the industry. 3D printing of Smart Bay Branch Park brings together the Chinese Cultural Museum, the largest 3D printing bridge in the world, the pier and other art played red dot networks; the Shanghai Glass Museum has transformed from a glass furnace workshop to a magical change, colorful crystal glass world, China, China, China It is one of the three museums, not to be missed; the third -floor bridge sports cultural park, which was previously known as the Shanghai nitrate vacuum bottle factory, has become a new generation of red tide drift fist.

　　Baoshan District: Explore the villages north of Shanghai, "quiet" color

　　The national characteristics of the north gate of Shanghai -Luo Jing, Tangwan Town, starfish, bonuses, new land, and Yangqiao Village will build a "five villages scalable" rural revitalization demonstration zone. Tangwan’s most beautiful rural village road. The Shanghai New Road series comes from "fields, forests, roads, rivers, houses" this is a maternal cultural park hemerocallis flower, grass prostitute troubles, golden rice fields, adopt non -genetic technology entertainment; village in the village; in the village Starfish, Jellyfish Postal House Dating "Water Elf" Bath Water System Forest Oxygen Bar Spa, looking up at the sky and star camp, "crab accidentally meet" Baoshan Lake Yangtze River Crab, enjoying leisurely and pleasant rural life.

Zhitong Finance APP News, Seventh Avenue (00797) issued an announcement that on March 15, 2022, the company indirectly wholly wholly -owned subsidiary Shanghai Ling Su and the lessor Shanghai Yuncheng Financial Leasing shall establish a financial leasing agreement. RMB 150 million sells rental assets to the lessor, and the lessor must rent the lease asset from Shanghai Ling Su at 48 months.

It is reported that rental assets include 2790 hosts, 9,800 graphics cards and 150 servers.

According to the announcement, since the cloud computing business began in April 2021, the Group has purchased various models of graphics cards, computer hosts, servers and other cloud computing accessories, so that the group can provide cloud computing services and create value for its shareholders.

The company believes that the financial leasing arrangement is the group’s additional liquidity, and the financing cost is fair and reasonable. The group can continue to use leased assets for existing cloud business, which is beneficial to the company and complies with the overall interests of its shareholders. Due to the international financial reporting standards, the transfer of financial leasing arrangements that have not actual asset value will not generate any income or losses in its comprehensive financial statements. The expected transfer agreement will be used to supplement liquidity for the group’s operations, including but not limited to the development and operation of the game business and the expansion of cloud computing business.